ZLAB Zai Lab Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

ZLAB [NASD]

Zai Lab Limited

Healthcare | Biotechnology | China

statements

Index	-	P/E	-	EPS (ttm)	-3.40	Insider Own	7.64%	Shs Outstand	73.85M	Perf Week	-4.79%
Market Cap	15.01B	Forward P/E	-	EPS next Y	-3.30	Insider Trans	0.00%	Shs Float	55.69M	Perf Month	19.43%
Income	-240.40M	PEG	-	EPS next Q	-0.99	Inst Own	59.70%	Short Float	6.32%	Perf Quarter	7.48%
Sales	28.80M	P/S	521.11	EPS this Y	-14.60%	Inst Trans	0.01%	Short Ratio	9.69	Perf Half Y	35.30%
Book/sh	6.30	P/B	13.90	EPS next Y	0.00%	ROA	-55.20%	Target Price	99.38	Perf Year	166.65%
Cash/sh	2.70	P/C	32.37	EPS next 5Y	-	ROE	-64.50%	52W Range	29.43 - 95.51	Perf YTD	110.48%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-67.50%	52W High	-8.35%	Beta	-
Dividend %	-	Quick Ratio	8.50	Sales past 5Y	-	Gross Margin	72.70%	52W Low	197.45%	ATR	3.61
Employees	692	Current Ratio	8.60	Sales Q/Q	461.80%	Oper. Margin	-	RSI (14)	53.72	Volatility	4.05% 4.20%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	1.50%	Profit Margin	-	Rel Volume	0.47	Prev Close	87.47
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 13 BMO	Payout	-	Avg Volume	363.25K	Price	87.54
Recom	1.60	SMA20	2.05%	SMA50	6.73%	SMA200	27.73%	Volume	171,062	Change	0.08%

Apr-28-20

Initiated

Goldman

Buy

Apr-15-20

Initiated

Guggenheim

Buy

$75

Jul-12-19

Initiated

BofA/Merrill

Buy

Jul-05-19

Initiated

Macquarie

Outperform

Jan-29-19

Initiated

Credit Suisse

Outperform

Nov-21-18

Initiated

Jefferies

Buy

Jun-21-18

Resumed

Leerink Partners

Outperform

$43

Feb-14-18

Upgrade

JP Morgan

Neutral → Overweight

Oct-16-17

Initiated

Leerink Partners

Outperform

$42

Oct-16-17

Initiated

JP Morgan

Neutral

$32

Oct-09-20 08:48AM	Zai Lab Announces Full Exercise of the Over-allotment Option GlobeNewswire
Oct-06-20 07:30AM	Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer GlobeNewswire
Oct-05-20 07:30AM	Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC GlobeNewswire
Sep-28-20 08:35PM	Hedge Funds Slowly Warming Up To Zai Lab Limited (ZLAB) Insider Monkey
07:30AM	Zai Lab Announces Closing of Hong Kong Secondary Listing GlobeNewswire
Sep-27-20 11:26PM	Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX PR Newswire
11:21PM	Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX PR Newswire
Sep-22-20 07:53AM	Zai Lab Announces Pricing of Hong Kong Secondary Listing GlobeNewswire
06:34AM	ZTO Express Raises $1.27 Billion in Hong Kong Listing Bloomberg
Sep-19-20 07:30AM	Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer GlobeNewswire
Sep-17-20 05:30AM	Baozun, Zai Lab join march of New York-listed companies to raise more capital in Hong Kong as US-China ties deteriorate South China Morning Post
Sep-16-20 07:15AM	Zai Lab Launches Hong Kong Secondary Listing GlobeNewswire
Sep-10-20 09:18AM	Can You Imagine How Jubilant Zai Lab's (NASDAQ:ZLAB) Shareholders Feel About Its 132% Share Price Gain? Simply Wall St. -5.73%
07:30AM	Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China GlobeNewswire
Sep-03-20 07:30AM	Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020 GlobeNewswire
Aug-31-20 07:30AM	Zai Lab Announces Upcoming Participation in September Conferences GlobeNewswire
Aug-19-20 10:26AM	Billionaire Ray Dalio Snaps Up These 3 Strong Buy Stocks TipRanks
Aug-17-20 07:30AM	Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer GlobeNewswire
Aug-13-20 08:00PM	Zai Lab Limited (ZLAB) Q2 2020 Earnings Call Transcript Motley Fool
10:38AM	Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates PR Newswire
07:30AM	Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates GlobeNewswire
Aug-04-20 07:30AM	Zai Lab Announces NDA for Ripretinib Granted Priority Review by Chinas NMPA GlobeNewswire
Aug-02-20 09:08AM	3 Monster Growth Stocks That Are Still Undervalued TipRanks
Jul-30-20 07:30AM	Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates GlobeNewswire
Jul-20-20 10:39AM	China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor PR Newswire
07:30AM	China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor GlobeNewswire
Jul-16-20 06:31PM	Were Hedge Funds Right About Zai Lab Limited (ZLAB)? Insider Monkey
Jul-07-20 11:37PM	Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China PR Newswire
07:30AM	Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China GlobeNewswire
Jun-17-20 02:03PM	Do Hedge Funds Love Zai Lab Limited (ZLAB)? Insider Monkey
May-28-20 07:05PM	Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer PR Newswire
07:37AM	Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer GlobeNewswire
May-27-20 07:30AM	Zai Lab Announces Presentations at June Conferences GlobeNewswire
May-18-20 09:45PM	Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam- Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections PR Newswire
07:30AM	Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections GlobeNewswire
May-13-20 10:10AM	China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Business Wire
May-11-20 11:14AM	Optimism Runs High for MacroGenics GuruFocus.com +6.06%
May-08-20 01:18PM	The Top 5 Buys of the Matthews Asia Small Companies Fund GuruFocus.com
May-06-20 07:30AM	Zai Lab Announces NDA for Omadacycline Granted Priority Review by Chinas NMPA GlobeNewswire
Apr-30-20 07:30AM	Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference GlobeNewswire
Apr-16-20 07:30AM	Zai Lab Announces Chinas NMPA Grants Priority Review to the sNDA for ZEJULA (Niraparib) for First-Line Ovarian Cancer Maintenance Treatment GlobeNewswire
Apr-08-20 06:00AM	Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) GlobeNewswire +7.30%
Mar-28-20 09:09PM	Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB) Insider Monkey
Mar-19-20 12:21PM	Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates PR Newswire
11:30AM	Is Zai Lab Limited Unsponsored (ZLAB) Outperforming Other Medical Stocks This Year? Zacks
07:30AM	Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates GlobeNewswire
06:30AM	Zai Lab Ltd. to Host Earnings Call ACCESSWIRE
Mar-16-20 07:30AM	Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA GlobeNewswire -13.82%
Mar-05-20 07:30AM	Zai Lab to Announce Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates on March 19, 2020 GlobeNewswire
Feb-11-20 07:30AM	Zai Lab Announces Upcoming Participation at February Conferences GlobeNewswire
07:23AM	The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
06:47AM	Will Zai Lab Continue to Surge Higher? Zacks
Feb-10-20 07:30AM	Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA GlobeNewswire +5.01%
Feb-04-20 07:30AM	Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies GlobeNewswire
Jan-27-20 04:30PM	Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option GlobeNewswire
Jan-22-20 09:43PM	Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire -7.02%
Jan-21-20 04:34PM	Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Jan-14-20 07:30AM	Zai Lab Appoints Lonnie Moulder to Board of Directors GlobeNewswire +10.62%
Jan-09-20 07:30AM	Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer GlobeNewswire
Dec-30-19 06:55AM	How Does Zai Lab Limited (NASDAQ:ZLAB) Affect Your Portfolio Volatility? Simply Wall St.
Dec-27-19 08:46AM	Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB Benzinga +5.28%
07:41AM	Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer GlobeNewswire
Dec-23-19 07:30AM	Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-19 07:30AM	Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board GlobeNewswire -6.04%
Dec-08-19 06:26PM	Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB) Insider Monkey
Oct-30-19 07:30AM	Zai Lab Announces Upcoming Presentations at November Conferences GlobeNewswire
Oct-27-19 04:16PM	Heres What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
Oct-25-19 08:30AM	Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer GlobeNewswire +5.22%
Oct-24-19 08:30AM	Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer GlobeNewswire
Oct-04-19 07:30AM	Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference GlobeNewswire
Sep-29-19 02:15PM	Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer GlobeNewswire
Sep-11-19 12:22PM	Should Zai Lab (NASDAQ:ZLAB) Be Disappointed With Their 93% Profit? Simply Wall St.
Sep-03-19 06:01PM	Zai Lab Limited (ZLAB) Q2 2019 Earnings Call Transcript Motley Fool
07:32AM	Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 GlobeNewswire
06:30AM	Zai Lab Ltd. to Host Earnings Call ACCESSWIRE
Aug-27-19 07:30AM	Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients GlobeNewswire -7.42%
Aug-26-19 07:30AM	Zai Lab Announces Upcoming Presentations at September Conferences GlobeNewswire
Aug-20-19 07:30AM	Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019 GlobeNewswire
Aug-12-19 07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China GlobeNewswire
07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China Business Wire
Jul-05-19 04:01PM	Here is What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
Jul-02-19 07:42AM	Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China MarketWatch
07:30AM	Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China GlobeNewswire
07:30AM	Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China Business Wire
Jun-24-19 05:00AM	China biotech groups spend billions on overseas drug candidates Financial Times
Jun-12-19 09:23AM	Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer GlobeNewswire
Jun-11-19 08:09AM	Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)? Simply Wall St.
07:00AM	Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China GlobeNewswire
07:00AM	Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China Business Wire
Jun-03-19 07:30AM	Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer GlobeNewswire
May-29-19 07:30AM	Zai Lab Announces Presentations at June Conferences GlobeNewswire
May-16-19 07:30AM	Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections GlobeNewswire
May-09-19 07:30AM	Zai Lab Announces Participation at Upcoming May Conferences GlobeNewswire
May-03-19 08:29PM	Heres What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
May-02-19 07:18PM	Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire
May-01-19 05:00PM	3 Top Chinese Stocks to Watch in May Motley Fool
04:05PM	Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Apr-17-19 07:30AM	Zai Lab to Host Analyst & Investor Day on April 30, 2019 GlobeNewswire
Mar-30-19 10:06AM	Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%? Simply Wall St.
Mar-12-19 07:30AM	Zai Lab Announces Presentations at March Conferences GlobeNewswire

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience